GPX4 degrader-2

GPX4 degrader-2 (Compound W25) (24-72 h) potently inhibits HCT-116 colorectal cancer cell viability with time-dependent efficacy, achieving IC₅₀ values of 4.17, 2.49 and 2.24 μM after 24. 48 and 72 h treatment^[1].
GPX4 degrader-2 (2.5-10 μM; 6 h) dose-dependently suppresses long-term colony formation of HCT-116 colorectal cancer cells and inhibits DNA synthesis^[1].
GPX4 degrader-2 (2.5-10 μM; 6-24 h) dose- and time-dependently accumulates lipid ROS in HCT-116 colorectal cancer cells^[1].
GPX4 degrader-2 (2.5-10 μM; 24 h) dose-dependently depletes intracellular GSH levels and increases intracellular MDA levels in HCT-116 colorectal cancer cells^[1].
GPX4 degrader-2 (2.5-10 μM; 6-24 h) dose-dependently downregulates GPX4 protein expression in HCT-116 colorectal cancer cells by promoting ubiquitin-proteasomal degradation^[1].
GPX4 degrader-2 (10 μM; 24 h) promotes ubiquitination of GPX4 protein in HCT-116 colorectal cancer cells^[1].
GPX4 degrader-2 (50-100 μM; 2 h) directly binds to GPX4 protein, protecting it from pronase E digestion in HCT-116 colorectal cancer cell lysates^[1].
GPX4 degrader-2 inhibits the enzymatic activity of human recombinant GPX4^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.